Illumina, Inc. (ILMN): Price and Financial Metrics
Illumina, Inc. (ILMN)
Today's Latest Price: $372.12 USD
Updated Jul 7 6:55pm
Add ILMN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
ILMN Stock Summary
- Illumina Inc's market capitalization of $55,770,330,000 is ahead of 96.73% of US-listed equities.
- ILMN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 568.92 -- higher than 93.63% of US-listed equities with positive expected earnings growth.
- The price/operating cash flow metric for Illumina Inc is higher than 93.31% of stocks in our set with a positive cash flow.
- Stocks with similar financial metrics, market capitalization, and price volatility to Illumina Inc are NTES, VMW, ATVI, EW, and SQ.
- Visit ILMN's SEC page to see the company's official filings. To visit the company's web site, go to www.illumina.com.
ILMN Stock Price Chart Technical Analysis Charts
ILMN Price/Volume Stats
| Current price | $372.12 | 52-week high | $384.21 |
| Prev. close | $379.39 | 52-week low | $196.78 |
| Day low | $369.11 | Volume | 719,800 |
| Day high | $378.79 | Avg. volume | 1,252,924 |
| 50-day MA | $346.89 | Dividend yield | N/A |
| 200-day MA | $311.06 | Market Cap | 54.70B |
Illumina, Inc. (ILMN) Company Bio
Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. The company's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company was founded in 1998 and is based in San Diego, California.
ILMN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $372.12 | $121.46 | -67% |
We started the process of determining a valid price forecast for Illumina Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Illumina Inc ranked in the 23th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Illumina Inc, consider:
- The company's debt burden, as measured by earnings divided by interest payments, is 23.21 -- which is good for besting 86.44% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately only 10.65% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- ILMN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 50.64% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -68% |
| 1% | -68% |
| 2% | -67% |
| 3% | -67% |
| 4% | -67% |
| 5% | -66% |
BHC, MD, MTD, WST, and ABT can be thought of as valuation peers to ILMN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...